How should calciphylaxis be managed in a patient with end‑stage renal disease on dialysis?

Management of Calciphylaxis in End-Stage Renal Disease on Dialysis

Calciphylaxis requires immediate multimodal intervention with sodium thiosulfate as first-line therapy, discontinuation of warfarin and vitamin D sterols, aggressive wound care, and parathyroidectomy for patients with PTH >500 pg/mL. 1

Immediate First-Line Interventions

Sodium Thiosulfate Therapy

• Initiate sodium thiosulfate 12.5-25 g intravenously 2-3 times per week during the last hour of each hemodialysis session for 3-6 months. 1
• This represents the primary pharmacologic intervention with evidence of complete remission in 52% and partial remission in 19% of patients when used consistently in a multi-interventional approach. 2
• Early and consistent therapy with sodium thiosulfate improves disease outcomes, though mortality remains high at 40-80% at one year. 3, 2

Discontinue High-Risk Medications

• Stop warfarin immediately—vitamin K antagonists increase calciphylaxis risk up to 11-fold in ESRD patients. 1, 4
• Switch to reduced-dose apixaban if anticoagulation is required for atrial fibrillation, as non-vitamin K oral anticoagulants are safer alternatives. 1
• Discontinue all active vitamin D sterols (calcitriol, paricalcitol, doxercalciferol) immediately. 1, 4
• Stop calcium-containing phosphate binders and calcium supplements to prevent further calcium loading. 1, 4
• Discontinue iron supplementation. 4

Mineral-Bone Disorder Management

Reduce Calcium Loading

• Lower dialysate calcium concentration to 1.5-2.0 mEq/L (instead of standard 2.5 mEq/L) to avoid positive calcium balance. 1
• The standard dialysate calcium creates a diffusion gradient that promotes net calcium influx when combined with calcium-based phosphate binders. 1
• Eliminate calcium-containing phosphate binders entirely and switch to non-calcium alternatives (sevelamer or lanthanum). 5, 1

Address PTH Levels Based on Phenotype

• For patients with PTH >500 pg/mL: perform parathyroidectomy. 1, 6
• Parathyroidectomy combined with intensified dialysis and sodium thiosulfate can achieve complete lesion resolution within 3 months. 6
• For patients with low PTH (<150 pg/mL) and adynamic bone disease: discontinue all vitamin D therapy and allow PTH to rise to 150-300 pg/mL. 1
• Low-PTH calciphylaxis represents a contemporary phenotype where oversuppression of PTH eliminates the skeleton's calcium-buffering capacity, promoting soft tissue calcification. 1

Monitor Inflammatory Markers

• Measure C-reactive protein—the most helpful laboratory test for calciphylaxis diagnosis and monitoring. 1
• Elevated CRP is associated with increased calciphylaxis risk and predicts mortality. 1, 2

Wound Care and Pain Management

Wound Management

• Perform careful debridement of necrotic tissue, avoiding aggressive trauma to vulnerable tissue. 1
• Apply appropriate wound dressings and implement pressure relief strategies for thigh ulcers. 1
• Track wound healing progress with regular photographic documentation. 1
• Ensure meticulous wound inspection and cleansing at each dialysis session. 1

Pain Control

• Prioritize aggressive pain management—calciphylaxis lesions are extremely painful and require opioids as first-line therapy. 1, 7
• Paracetamol should be used universally as the preferred first-choice adjuvant agent. 7
• Consider early referral to palliative care specialists, though only 3% of renal physicians currently refer at diagnosis. 7

Dialysis Intensification

• Intensify peritoneal dialysis regimen or increase hemodialysis frequency to enhance clearance of uremic toxins and improve calcium-phosphate balance. 6, 8
• Successful cases demonstrate complete resolution with intensified dialysis combined with other interventions. 6

Diagnostic Considerations

Clinical Recognition

• Calciphylaxis presents as profoundly painful ischemic skin lesions with necrosis, typically on the abdomen and lower extremities where subcutaneous tissue is abundant. 3, 6
• Proximal-type calciphylaxis (trunk, thighs) carries worse prognosis than distal-type (lower legs, feet). 2

Avoid Skin Biopsy When Possible

• Skin biopsy has variable sensitivity (20-80%) and is not recommended due to risk of traumatizing vulnerable tissue and lack of validated histologic criteria. 1
• Diagnosis should be made clinically when characteristic lesions are present in the appropriate context. 1

Imaging Findings

• Radiographs reveal fine reticular and confluent patterns of subcutaneous calcifications. 9
• CT provides detailed visualization of extensive calcific deposits within soft tissues and musculature. 9, 10

Prognostic Factors and Monitoring

Poor Prognostic Indicators

• Proximal-type calciphylaxis, higher disease severity score at diagnosis, elevated CRP, older age, and need for antibiotics predict mortality. 2
• Non-survivors show lower remission rates during treatment. 2

Ongoing Surveillance

• Monitor wound healing, inflammatory markers (CRP), and vascular calcification progression regularly. 1
• Maintain hemoglobin >12 g/dL for women, >13 g/dL for men, and serum bicarbonate ≥22 mmol/L. 1

Advance Care Planning

• Initiate advance care planning discussions early—72% of specialists undertake these discussions given the 40-80% one-year mortality rate. 1, 7
• Shared decision-making is essential given the high mortality from sepsis secondary to infected ulcers. 1, 3

Critical Pitfalls to Avoid

• Never continue warfarin—this is the single most modifiable risk factor with an 11-fold increased risk. 1
• Never continue active vitamin D therapy—this promotes calcium loading and worsens vascular calcification. 1, 4
• Never use calcium-based phosphate binders—these contribute significant calcium intake that overwhelms protective mechanisms. 1
• Never target normal PTH levels in dialysis patients—suppression below 150 pg/mL causes adynamic bone disease and increases calciphylaxis risk. 1
• Recognize that serum calcium and phosphate levels are NOT predictive of calciphylaxis development—patients can develop this condition even with normal mineral levels. 1